Watanabe Toru | Hematology And Stem Cell Transplantation Division National Cancer Center Hospital

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy : case report and review of the literature
Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma
Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma : morphological, immunohistochemical, and FISH analyses
Nocardia exalbida brain abscess in a patient with follicular lymphoma
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (^Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
t(11 ; 18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine
Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings
Primary Mediastinal Large B-Cell Lymphoma : A Single-Institution Clinical Study in Japan
EBV-Positive Burkitt Lymphoma as a Late-Onset Posttransplantion Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation
Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type : A Case Report and Review of the Literature
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
CD44 Variant Isoform Expression and Breast Cancer Prognosis
Concordance in Pathological Response to Neoadjuvant Chemotherapy between Invasive and Noninvasive Components of Primary Breast Carcinomas
Two Special Types of Breast Cancer Presenting as Progressive Disease after Neoadjuvant Chemotherapy with Docetaxel plus Doxorubicin
Evaluation of Histopathological Criteria for Identifying Node-negative Breast Cancer with High Risk of Early Recurrence in the NSAS-BC Protocol Study
Seven Cases of Breast Cancer Recurrence Limited to the Central Nervous System without Other Visceral Metastases
Evaluation of HER2 Status: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody (Trastuzumab) (Pathological Committee for Optimal Use of Trastuzumab)
Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia : a single-center analysis of 47 patients
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3-Hour Infusion of Paclitaxel
Tumor-associated Fever in Recurrent Breast Cancer with Liver Metastases
A quantitative model using mean and standard deviation for evaluation of interobserver agreement in nuclear atypia scoring of breast carcinomas in a protocol study
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma

もっと見る

スポンサーリンク